Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colonic Neoplasms | 88 | 2024 | 2541 | 12.090 |
Why?
|
Colorectal Neoplasms | 221 | 2023 | 6773 | 11.480 |
Why?
|
Chemotherapy, Adjuvant | 49 | 2023 | 3479 | 3.100 |
Why?
|
Fluorouracil | 46 | 2023 | 1619 | 2.940 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 81 | 2023 | 11524 | 2.910 |
Why?
|
Rectal Neoplasms | 20 | 2024 | 1206 | 2.620 |
Why?
|
Neoplasm Recurrence, Local | 48 | 2023 | 9239 | 2.540 |
Why?
|
Microsatellite Instability | 44 | 2023 | 684 | 2.470 |
Why?
|
Exercise | 32 | 2023 | 5615 | 2.240 |
Why?
|
Neoplasm Staging | 87 | 2023 | 11031 | 2.010 |
Why?
|
Diet | 35 | 2023 | 7939 | 2.000 |
Why?
|
Leucovorin | 31 | 2023 | 628 | 1.990 |
Why?
|
Disease-Free Survival | 49 | 2023 | 6895 | 1.670 |
Why?
|
Life Style | 17 | 2022 | 3835 | 1.570 |
Why?
|
Adenocarcinoma | 29 | 2023 | 6364 | 1.520 |
Why?
|
Camptothecin | 24 | 2022 | 576 | 1.510 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2023 | 990 | 1.360 |
Why?
|
Organoplatinum Compounds | 21 | 2021 | 408 | 1.350 |
Why?
|
Prospective Studies | 127 | 2024 | 53288 | 1.340 |
Why?
|
Liver Neoplasms | 22 | 2024 | 4253 | 1.330 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2022 | 685 | 1.290 |
Why?
|
Feeding Behavior | 16 | 2021 | 3188 | 1.250 |
Why?
|
Body Mass Index | 34 | 2022 | 12720 | 1.200 |
Why?
|
CpG Islands | 26 | 2023 | 1172 | 1.200 |
Why?
|
Leukemia | 4 | 2023 | 1511 | 1.170 |
Why?
|
Proportional Hazards Models | 63 | 2022 | 12354 | 1.150 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2024 | 2214 | 1.150 |
Why?
|
Aged | 219 | 2024 | 163280 | 1.130 |
Why?
|
Motor Activity | 12 | 2015 | 2714 | 1.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 37 | 2023 | 2043 | 1.100 |
Why?
|
Middle Aged | 230 | 2024 | 213383 | 1.060 |
Why?
|
Prognosis | 84 | 2023 | 29063 | 1.040 |
Why?
|
Humans | 399 | 2024 | 744343 | 1.020 |
Why?
|
Survivors | 12 | 2023 | 2291 | 0.990 |
Why?
|
Cyclooxygenase 2 Inhibitors | 4 | 2021 | 320 | 0.990 |
Why?
|
Exercise Therapy | 9 | 2020 | 906 | 0.980 |
Why?
|
Male | 266 | 2024 | 350118 | 0.970 |
Why?
|
Female | 279 | 2024 | 380194 | 0.970 |
Why?
|
Dietary Sucrose | 3 | 2018 | 246 | 0.930 |
Why?
|
Deoxycytidine | 11 | 2019 | 826 | 0.920 |
Why?
|
Adiposity | 10 | 2022 | 1807 | 0.910 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 13 | 2022 | 1038 | 0.870 |
Why?
|
Body Composition | 11 | 2023 | 2401 | 0.870 |
Why?
|
Follow-Up Studies | 75 | 2024 | 39050 | 0.850 |
Why?
|
Medical Oncology | 15 | 2023 | 2265 | 0.850 |
Why?
|
Antineoplastic Agents | 31 | 2024 | 13695 | 0.830 |
Why?
|
Survival Rate | 41 | 2022 | 12788 | 0.830 |
Why?
|
DNA Methylation | 36 | 2023 | 4286 | 0.790 |
Why?
|
ras Proteins | 21 | 2014 | 1060 | 0.790 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 2020 | 216 | 0.780 |
Why?
|
Hyperinsulinism | 5 | 2023 | 415 | 0.760 |
Why?
|
Intra-Abdominal Fat | 3 | 2021 | 591 | 0.760 |
Why?
|
Fusobacterium nucleatum | 5 | 2021 | 162 | 0.740 |
Why?
|
Secondary Prevention | 3 | 2021 | 1530 | 0.710 |
Why?
|
Survival Analysis | 34 | 2021 | 10252 | 0.710 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 4 | 2020 | 424 | 0.700 |
Why?
|
Cohort Studies | 64 | 2023 | 40561 | 0.700 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2023 | 271 | 0.700 |
Why?
|
Combined Modality Therapy | 19 | 2021 | 8642 | 0.690 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2020 | 93 | 0.690 |
Why?
|
Stomach Neoplasms | 10 | 2023 | 1333 | 0.680 |
Why?
|
Adiponectin | 3 | 2020 | 1100 | 0.660 |
Why?
|
Cyclooxygenase 2 | 9 | 2020 | 611 | 0.630 |
Why?
|
Quinazolines | 10 | 2013 | 1356 | 0.620 |
Why?
|
Adult | 149 | 2023 | 214055 | 0.620 |
Why?
|
Phosphatidylinositol 3-Kinases | 21 | 2021 | 2938 | 0.620 |
Why?
|
Long Interspersed Nucleotide Elements | 15 | 2020 | 338 | 0.620 |
Why?
|
Seafood | 2 | 2018 | 384 | 0.610 |
Why?
|
Neoplasms | 23 | 2024 | 21683 | 0.600 |
Why?
|
Kaplan-Meier Estimate | 30 | 2020 | 6538 | 0.590 |
Why?
|
Tumor Microenvironment | 13 | 2022 | 3586 | 0.590 |
Why?
|
Risk Factors | 73 | 2023 | 72290 | 0.580 |
Why?
|
Sarcopenia | 5 | 2020 | 368 | 0.570 |
Why?
|
Fatty Acids, Omega-3 | 4 | 2020 | 1344 | 0.570 |
Why?
|
Clinical Trials, Phase III as Topic | 9 | 2021 | 841 | 0.570 |
Why?
|
Aged, 80 and over | 66 | 2022 | 57776 | 0.570 |
Why?
|
Muscle, Skeletal | 8 | 2023 | 4931 | 0.560 |
Why?
|
Nutrition Policy | 2 | 2018 | 488 | 0.550 |
Why?
|
Obesity | 19 | 2020 | 12745 | 0.550 |
Why?
|
Carcinoma, Signet Ring Cell | 5 | 2018 | 83 | 0.540 |
Why?
|
Sweetening Agents | 2 | 2018 | 296 | 0.530 |
Why?
|
Colonic Polyps | 4 | 2022 | 542 | 0.530 |
Why?
|
Neoplasm Metastasis | 17 | 2019 | 4851 | 0.530 |
Why?
|
Coffee | 5 | 2022 | 578 | 0.520 |
Why?
|
Pancreatic Neoplasms | 14 | 2023 | 5256 | 0.510 |
Why?
|
Mutation | 49 | 2023 | 29786 | 0.510 |
Why?
|
Geriatric Assessment | 2 | 2013 | 1372 | 0.510 |
Why?
|
Dietary Fats | 3 | 2022 | 2017 | 0.510 |
Why?
|
C-Peptide | 6 | 2023 | 419 | 0.500 |
Why?
|
Fishes | 1 | 2018 | 569 | 0.500 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2020 | 2015 | 0.500 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3778 | 0.490 |
Why?
|
Glycemic Index | 3 | 2019 | 395 | 0.490 |
Why?
|
United States | 74 | 2023 | 69872 | 0.490 |
Why?
|
Meat Products | 2 | 2019 | 99 | 0.480 |
Why?
|
Population Surveillance | 4 | 2021 | 2616 | 0.480 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 22 | 2022 | 890 | 0.480 |
Why?
|
Body Weight | 5 | 2024 | 4669 | 0.480 |
Why?
|
Anus Neoplasms | 3 | 2024 | 332 | 0.470 |
Why?
|
Proto-Oncogene Proteins | 19 | 2014 | 4554 | 0.460 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2019 | 640 | 0.460 |
Why?
|
Dietary Supplements | 9 | 2020 | 3297 | 0.450 |
Why?
|
Physical Exertion | 2 | 2006 | 695 | 0.450 |
Why?
|
Energy Metabolism | 5 | 2016 | 2899 | 0.450 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 25 | 2023 | 1692 | 0.450 |
Why?
|
Metformin | 1 | 2020 | 835 | 0.450 |
Why?
|
Data Collection | 2 | 2013 | 3341 | 0.450 |
Why?
|
Aspirin | 9 | 2021 | 3282 | 0.450 |
Why?
|
Vitamin D | 11 | 2023 | 3223 | 0.450 |
Why?
|
Neuroendocrine Tumors | 6 | 2013 | 594 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2022 | 9959 | 0.430 |
Why?
|
Adenoma | 5 | 2022 | 2174 | 0.430 |
Why?
|
Adenocarcinoma, Mucinous | 5 | 2019 | 506 | 0.430 |
Why?
|
Dairy Products | 3 | 2021 | 498 | 0.430 |
Why?
|
Vitamins | 6 | 2023 | 1622 | 0.420 |
Why?
|
Patient Compliance | 3 | 2021 | 2684 | 0.420 |
Why?
|
Lymphatic Metastasis | 8 | 2021 | 2924 | 0.410 |
Why?
|
Weight Loss | 4 | 2024 | 2622 | 0.400 |
Why?
|
Esophageal Neoplasms | 6 | 2021 | 1583 | 0.390 |
Why?
|
Colectomy | 7 | 2020 | 683 | 0.390 |
Why?
|
Calcium, Dietary | 3 | 2019 | 526 | 0.390 |
Why?
|
Drug Administration Schedule | 13 | 2021 | 4933 | 0.390 |
Why?
|
Cardiovascular Diseases | 5 | 2022 | 15165 | 0.390 |
Why?
|
Insulin | 9 | 2019 | 6580 | 0.380 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 772 | 0.370 |
Why?
|
Antibodies, Monoclonal | 14 | 2014 | 9274 | 0.370 |
Why?
|
Blood Glucose | 3 | 2017 | 6256 | 0.370 |
Why?
|
Meat | 1 | 2013 | 592 | 0.360 |
Why?
|
California | 6 | 2020 | 1402 | 0.360 |
Why?
|
Recurrence | 7 | 2023 | 8340 | 0.360 |
Why?
|
Appendiceal Neoplasms | 2 | 2023 | 146 | 0.350 |
Why?
|
Risk Reduction Behavior | 2 | 2019 | 1125 | 0.350 |
Why?
|
Multivariate Analysis | 18 | 2021 | 12245 | 0.340 |
Why?
|
Overweight | 5 | 2016 | 2371 | 0.340 |
Why?
|
Carcinoma | 4 | 2017 | 2375 | 0.340 |
Why?
|
Gastroenterology | 1 | 2015 | 536 | 0.330 |
Why?
|
Esophagogastric Junction | 4 | 2019 | 313 | 0.330 |
Why?
|
Somatomedins | 2 | 2008 | 192 | 0.330 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7279 | 0.330 |
Why?
|
Yoga | 2 | 2022 | 253 | 0.320 |
Why?
|
Digestive System Surgical Procedures | 2 | 2004 | 576 | 0.320 |
Why?
|
Nuts | 3 | 2019 | 257 | 0.320 |
Why?
|
Anal Canal | 4 | 2023 | 376 | 0.310 |
Why?
|
Beverages | 4 | 2022 | 820 | 0.310 |
Why?
|
Dietary Fiber | 4 | 2019 | 760 | 0.310 |
Why?
|
Cisplatin | 6 | 2017 | 1662 | 0.300 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 2728 | 0.300 |
Why?
|
Health Behavior | 3 | 2015 | 2636 | 0.300 |
Why?
|
Treatment Outcome | 46 | 2023 | 63114 | 0.300 |
Why?
|
Inflammation | 3 | 2023 | 10638 | 0.290 |
Why?
|
beta Catenin | 8 | 2020 | 1059 | 0.290 |
Why?
|
Weight Gain | 1 | 2016 | 2292 | 0.280 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2278 | 0.280 |
Why?
|
Age Factors | 12 | 2021 | 18370 | 0.280 |
Why?
|
Risk Assessment | 23 | 2022 | 23338 | 0.280 |
Why?
|
Genes, ras | 4 | 2020 | 690 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 17 | 2023 | 20129 | 0.270 |
Why?
|
Receptors, Calcium-Sensing | 2 | 2017 | 315 | 0.270 |
Why?
|
Colostomy | 2 | 2018 | 99 | 0.270 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2007 | 295 | 0.270 |
Why?
|
Calcifediol | 2 | 2019 | 166 | 0.270 |
Why?
|
Recreation | 1 | 2006 | 115 | 0.270 |
Why?
|
Confidence Intervals | 4 | 2021 | 2971 | 0.270 |
Why?
|
Gallbladder Neoplasms | 1 | 2007 | 183 | 0.270 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2019 | 563 | 0.270 |
Why?
|
Radiation Tolerance | 2 | 2018 | 486 | 0.260 |
Why?
|
Energy Intake | 4 | 2018 | 2148 | 0.260 |
Why?
|
T-Lymphocyte Subsets | 3 | 2021 | 1838 | 0.260 |
Why?
|
Risk | 9 | 2021 | 9687 | 0.260 |
Why?
|
Colon | 5 | 2020 | 1772 | 0.260 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2007 | 1770 | 0.250 |
Why?
|
Comorbidity | 9 | 2022 | 10388 | 0.250 |
Why?
|
Interleukin-6 | 4 | 2023 | 3200 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 14 | 2018 | 8428 | 0.240 |
Why?
|
Dacarbazine | 4 | 2013 | 566 | 0.240 |
Why?
|
Hyperglycemia | 1 | 2013 | 1373 | 0.240 |
Why?
|
Pentoxifylline | 1 | 2023 | 55 | 0.230 |
Why?
|
Incidence | 20 | 2022 | 20947 | 0.230 |
Why?
|
Stomatitis, Aphthous | 1 | 2023 | 53 | 0.230 |
Why?
|
Breast Neoplasms | 5 | 2021 | 20822 | 0.220 |
Why?
|
Cause of Death | 7 | 2022 | 3584 | 0.220 |
Why?
|
Behcet Syndrome | 1 | 2023 | 84 | 0.220 |
Why?
|
Diet, Vegetarian | 2 | 2022 | 174 | 0.220 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 87 | 0.210 |
Why?
|
Bilirubin | 1 | 2004 | 425 | 0.210 |
Why?
|
Odds Ratio | 13 | 2018 | 9849 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 5 | 2017 | 2038 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4034 | 0.210 |
Why?
|
Bile Duct Neoplasms | 1 | 2007 | 567 | 0.200 |
Why?
|
Cholangiocarcinoma | 1 | 2007 | 516 | 0.200 |
Why?
|
Keloid | 1 | 2022 | 50 | 0.200 |
Why?
|
Quality of Life | 11 | 2023 | 12804 | 0.200 |
Why?
|
Retrospective Studies | 21 | 2024 | 77449 | 0.200 |
Why?
|
Carcinoid Tumor | 3 | 2013 | 235 | 0.200 |
Why?
|
Cholecalciferol | 2 | 2019 | 537 | 0.200 |
Why?
|
Creatine | 1 | 2023 | 421 | 0.200 |
Why?
|
Digestive System Neoplasms | 1 | 2021 | 87 | 0.200 |
Why?
|
Resistance Training | 2 | 2020 | 165 | 0.200 |
Why?
|
Young Adult | 19 | 2023 | 56430 | 0.190 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2022 | 140 | 0.190 |
Why?
|
Monosaccharides | 1 | 2021 | 70 | 0.190 |
Why?
|
Smoking | 6 | 2022 | 8987 | 0.190 |
Why?
|
Alkylating Agents | 1 | 2021 | 139 | 0.190 |
Why?
|
Sirolimus | 4 | 2013 | 1564 | 0.190 |
Why?
|
Fusobacterium Infections | 1 | 2021 | 53 | 0.190 |
Why?
|
Molecular Epidemiology | 4 | 2019 | 468 | 0.190 |
Why?
|
Laxatives | 1 | 2021 | 87 | 0.190 |
Why?
|
Societies, Medical | 3 | 2018 | 3743 | 0.190 |
Why?
|
Adenomatous Polyps | 1 | 2021 | 107 | 0.180 |
Why?
|
Health Personnel | 5 | 2024 | 3218 | 0.180 |
Why?
|
Nomograms | 1 | 2022 | 228 | 0.180 |
Why?
|
Flavonoids | 1 | 2023 | 443 | 0.180 |
Why?
|
Attitude to Health | 2 | 2019 | 2052 | 0.180 |
Why?
|
Alcohol Drinking | 4 | 2018 | 3966 | 0.180 |
Why?
|
Gastrointestinal Motility | 1 | 2021 | 225 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2006 | 2455 | 0.180 |
Why?
|
Vitamin D-Binding Protein | 1 | 2020 | 129 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 2282 | 0.170 |
Why?
|
Research Subjects | 1 | 2021 | 239 | 0.170 |
Why?
|
Chemoprevention | 1 | 2022 | 319 | 0.170 |
Why?
|
Autophagy | 2 | 2020 | 1300 | 0.170 |
Why?
|
Immunohistochemistry | 15 | 2021 | 11366 | 0.170 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2021 | 241 | 0.170 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1660 | 0.170 |
Why?
|
Caffeine | 3 | 2020 | 699 | 0.170 |
Why?
|
Granulocytes | 1 | 2021 | 548 | 0.170 |
Why?
|
Bifidobacteriales Infections | 1 | 2018 | 10 | 0.170 |
Why?
|
Endpoint Determination | 2 | 2020 | 601 | 0.170 |
Why?
|
Paraffin Embedding | 1 | 2020 | 299 | 0.170 |
Why?
|
Tissue Fixation | 1 | 2020 | 241 | 0.170 |
Why?
|
Nutrition Surveys | 1 | 2005 | 1660 | 0.170 |
Why?
|
Genes, DCC | 2 | 2001 | 12 | 0.160 |
Why?
|
Maximum Tolerated Dose | 3 | 2012 | 892 | 0.160 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 316 | 0.160 |
Why?
|
Formaldehyde | 1 | 2020 | 353 | 0.160 |
Why?
|
American Cancer Society | 2 | 2022 | 61 | 0.160 |
Why?
|
Adipose Tissue | 5 | 2023 | 3279 | 0.160 |
Why?
|
Escherichia coli Infections | 1 | 2022 | 532 | 0.160 |
Why?
|
Phenylurea Compounds | 3 | 2024 | 528 | 0.160 |
Why?
|
Bifidobacterium | 1 | 2018 | 100 | 0.160 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2021 | 262 | 0.160 |
Why?
|
Muscular Disorders, Atrophic | 1 | 2018 | 33 | 0.160 |
Why?
|
Databases, Factual | 8 | 2021 | 7729 | 0.150 |
Why?
|
DNA, Neoplasm | 8 | 2023 | 1758 | 0.150 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 68 | 0.150 |
Why?
|
Up-Regulation | 6 | 2019 | 4217 | 0.150 |
Why?
|
Lymph Nodes | 3 | 2021 | 3474 | 0.150 |
Why?
|
Sex Factors | 6 | 2020 | 10397 | 0.150 |
Why?
|
Hypoglycemic Agents | 2 | 2020 | 2872 | 0.150 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 665 | 0.150 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2019 | 251 | 0.150 |
Why?
|
Disease Progression | 5 | 2019 | 13284 | 0.140 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 319 | 0.140 |
Why?
|
Administration, Oral | 6 | 2016 | 3913 | 0.140 |
Why?
|
Chimerin Proteins | 1 | 2016 | 7 | 0.140 |
Why?
|
Self Care | 2 | 2019 | 786 | 0.140 |
Why?
|
Fish Oils | 2 | 2019 | 470 | 0.140 |
Why?
|
Fructose | 2 | 2022 | 288 | 0.140 |
Why?
|
Nurses | 6 | 2020 | 2461 | 0.140 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2017 | 379 | 0.140 |
Why?
|
Critical Pathways | 1 | 2020 | 476 | 0.140 |
Why?
|
SEER Program | 5 | 2021 | 1508 | 0.140 |
Why?
|
Medicare | 4 | 2012 | 6566 | 0.140 |
Why?
|
DNA Repair Enzymes | 2 | 2008 | 349 | 0.140 |
Why?
|
Phenotype | 13 | 2023 | 16365 | 0.140 |
Why?
|
Pyridines | 3 | 2014 | 2825 | 0.140 |
Why?
|
Case-Control Studies | 8 | 2022 | 21746 | 0.140 |
Why?
|
Respiratory Tract Diseases | 1 | 2021 | 722 | 0.130 |
Why?
|
Continuity of Patient Care | 1 | 2003 | 1049 | 0.130 |
Why?
|
Positron-Emission Tomography | 3 | 2021 | 6234 | 0.130 |
Why?
|
Pancreaticoduodenectomy | 1 | 2019 | 503 | 0.130 |
Why?
|
Epidemiologic Studies | 3 | 2016 | 676 | 0.130 |
Why?
|
Nerve Growth Factors | 1 | 1999 | 574 | 0.130 |
Why?
|
Telomere | 1 | 2022 | 910 | 0.130 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3703 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2003 | 1359 | 0.130 |
Why?
|
Folic Acid | 2 | 2015 | 1300 | 0.130 |
Why?
|
Radiopharmaceuticals | 3 | 2021 | 2645 | 0.130 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2727 | 0.130 |
Why?
|
Tertiary Prevention | 1 | 2015 | 9 | 0.130 |
Why?
|
Forecasting | 2 | 2022 | 2951 | 0.130 |
Why?
|
Genes, p16 | 2 | 2017 | 157 | 0.130 |
Why?
|
Registries | 4 | 2020 | 8089 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2020 | 3616 | 0.130 |
Why?
|
Adipokines | 1 | 2017 | 319 | 0.130 |
Why?
|
Treatment Failure | 1 | 2021 | 2618 | 0.130 |
Why?
|
Folic Acid Deficiency | 1 | 2015 | 115 | 0.130 |
Why?
|
Dideoxynucleosides | 1 | 2015 | 122 | 0.130 |
Why?
|
Tooth Loss | 1 | 2016 | 197 | 0.130 |
Why?
|
Melanoma | 2 | 2023 | 5510 | 0.120 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15076 | 0.120 |
Why?
|
Multicenter Studies as Topic | 4 | 2022 | 1677 | 0.120 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 2274 | 0.120 |
Why?
|
Lymphocyte Count | 4 | 2020 | 793 | 0.120 |
Why?
|
Age of Onset | 1 | 2021 | 3271 | 0.120 |
Why?
|
Calcium Signaling | 1 | 2019 | 721 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1329 | 0.120 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3176 | 0.120 |
Why?
|
Neurotoxicity Syndromes | 1 | 2018 | 290 | 0.120 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2015 | 176 | 0.120 |
Why?
|
Loss of Heterozygosity | 4 | 2009 | 684 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 975 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2023 | 11725 | 0.120 |
Why?
|
Pilot Projects | 7 | 2023 | 8324 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2016 | 357 | 0.120 |
Why?
|
Pathology, Molecular | 2 | 2017 | 326 | 0.120 |
Why?
|
Health Care Surveys | 1 | 2021 | 2453 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2009 | 365 | 0.120 |
Why?
|
Adolescent | 14 | 2023 | 85781 | 0.120 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11124 | 0.120 |
Why?
|
Hepatitis C | 1 | 2024 | 1591 | 0.120 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7913 | 0.110 |
Why?
|
DNA, Bacterial | 1 | 2018 | 1465 | 0.110 |
Why?
|
Metabolome | 1 | 2020 | 895 | 0.110 |
Why?
|
Muscles | 1 | 2018 | 1614 | 0.110 |
Why?
|
Intestine, Small | 1 | 2019 | 1241 | 0.110 |
Why?
|
Periodontal Diseases | 1 | 2016 | 449 | 0.110 |
Why?
|
Hospitals | 2 | 2004 | 3952 | 0.110 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1613 | 0.110 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 173 | 0.110 |
Why?
|
Ontario | 1 | 2013 | 383 | 0.110 |
Why?
|
Vitamin D Deficiency | 2 | 2013 | 1343 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1581 | 0.110 |
Why?
|
Walking | 1 | 2020 | 1180 | 0.110 |
Why?
|
Cholesterol | 1 | 2022 | 2917 | 0.110 |
Why?
|
Social Class | 1 | 2021 | 1999 | 0.110 |
Why?
|
Germ-Line Mutation | 4 | 2018 | 1788 | 0.110 |
Why?
|
Television | 1 | 2015 | 409 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3255 | 0.110 |
Why?
|
Diet Records | 3 | 2020 | 425 | 0.110 |
Why?
|
Codon | 1 | 2014 | 611 | 0.110 |
Why?
|
Adolescent Behavior | 1 | 2021 | 1151 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2022 | 10180 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 5 | 2017 | 2849 | 0.100 |
Why?
|
Diet, Mediterranean | 2 | 2019 | 700 | 0.100 |
Why?
|
Insurance Claim Review | 1 | 2016 | 720 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1897 | 0.100 |
Why?
|
Income | 1 | 2021 | 1913 | 0.100 |
Why?
|
Biomedical Research | 3 | 2019 | 3309 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1587 | 0.100 |
Why?
|
Brain Neoplasms | 3 | 2021 | 8863 | 0.100 |
Why?
|
Residence Characteristics | 1 | 2021 | 2050 | 0.100 |
Why?
|
Neuroblastoma | 2 | 2001 | 1226 | 0.100 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9438 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 5 | 2023 | 5535 | 0.100 |
Why?
|
Vitamin B 6 | 1 | 2013 | 237 | 0.100 |
Why?
|
Tegafur | 2 | 2013 | 49 | 0.100 |
Why?
|
Time Factors | 12 | 2021 | 40075 | 0.100 |
Why?
|
Epigenomics | 2 | 2017 | 903 | 0.100 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 2 | 2009 | 85 | 0.100 |
Why?
|
Monocytes | 1 | 2021 | 2596 | 0.100 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 426 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1411 | 0.100 |
Why?
|
Cell Lineage | 1 | 2020 | 2504 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2009 | 323 | 0.100 |
Why?
|
Vitamin B Complex | 1 | 2013 | 288 | 0.090 |
Why?
|
Physical Fitness | 2 | 2013 | 733 | 0.090 |
Why?
|
Interdisciplinary Communication | 2 | 2015 | 950 | 0.090 |
Why?
|
Gastrectomy | 2 | 2007 | 663 | 0.090 |
Why?
|
Lymphocytes | 3 | 2020 | 2617 | 0.090 |
Why?
|
Dietary Carbohydrates | 2 | 2012 | 906 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 1 | 2011 | 295 | 0.090 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2008 | 271 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 412 | 0.090 |
Why?
|
Diet Therapy | 1 | 2011 | 154 | 0.090 |
Why?
|
Enkephalins | 1 | 1990 | 154 | 0.090 |
Why?
|
Animals | 14 | 2022 | 168757 | 0.090 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2011 | 314 | 0.090 |
Why?
|
MicroRNAs | 2 | 2016 | 3752 | 0.090 |
Why?
|
Epidemiology | 1 | 2013 | 287 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4560 | 0.090 |
Why?
|
MutS Homolog 2 Protein | 3 | 2017 | 200 | 0.090 |
Why?
|
Genes, bcl-1 | 1 | 2009 | 11 | 0.090 |
Why?
|
Intestinal Perforation | 1 | 2012 | 253 | 0.090 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2009 | 82 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1863 | 0.090 |
Why?
|
HLA-DR Antigens | 2 | 2021 | 645 | 0.090 |
Why?
|
Calcium | 2 | 2019 | 5756 | 0.090 |
Why?
|
Insulin Resistance | 2 | 2021 | 3864 | 0.080 |
Why?
|
Central Nervous System Stimulants | 1 | 2017 | 1148 | 0.080 |
Why?
|
Rectum | 3 | 2019 | 904 | 0.080 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2009 | 285 | 0.080 |
Why?
|
Nausea | 2 | 2016 | 673 | 0.080 |
Why?
|
Telephone | 1 | 2011 | 617 | 0.080 |
Why?
|
Tea | 2 | 2023 | 275 | 0.080 |
Why?
|
Health Occupations | 2 | 2021 | 224 | 0.080 |
Why?
|
Quinolines | 1 | 2013 | 732 | 0.080 |
Why?
|
Biliary Tract Neoplasms | 1 | 2009 | 178 | 0.080 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 625 | 0.080 |
Why?
|
Safety | 1 | 2012 | 1186 | 0.080 |
Why?
|
Albumins | 2 | 2023 | 569 | 0.080 |
Why?
|
Logistic Models | 6 | 2022 | 13408 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2009 | 627 | 0.080 |
Why?
|
Pandemics | 3 | 2022 | 8388 | 0.080 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 391 | 0.080 |
Why?
|
Research Design | 3 | 2020 | 5987 | 0.080 |
Why?
|
Standard of Care | 1 | 2011 | 564 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13102 | 0.070 |
Why?
|
Mass Screening | 1 | 2003 | 5255 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2021 | 2016 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1634 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3086 | 0.070 |
Why?
|
Receptors, Calcitriol | 1 | 2009 | 350 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3528 | 0.070 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2010 | 611 | 0.070 |
Why?
|
Models, Statistical | 1 | 2022 | 5102 | 0.070 |
Why?
|
Decision Making | 3 | 2020 | 3887 | 0.070 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2014 | 1222 | 0.070 |
Why?
|
Testis | 1 | 1990 | 803 | 0.070 |
Why?
|
Models, Genetic | 1 | 2017 | 3494 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 41 | 0.070 |
Why?
|
DNA Modification Methylases | 1 | 2007 | 206 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2021 | 2505 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5720 | 0.070 |
Why?
|
Prevalence | 4 | 2023 | 15226 | 0.070 |
Why?
|
Preoperative Care | 3 | 2023 | 2250 | 0.070 |
Why?
|
Genes | 1 | 1990 | 1893 | 0.070 |
Why?
|
Inflammation Mediators | 1 | 2015 | 1889 | 0.070 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 627 | 0.070 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 1799 | 0.070 |
Why?
|
Tocopherols | 1 | 2005 | 43 | 0.070 |
Why?
|
Endostatins | 1 | 2006 | 174 | 0.070 |
Why?
|
RNA-Binding Proteins | 2 | 2012 | 1903 | 0.070 |
Why?
|
Protein Precursors | 1 | 1990 | 1154 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2007 | 7880 | 0.070 |
Why?
|
Surgery Department, Hospital | 1 | 2007 | 175 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2009 | 604 | 0.060 |
Why?
|
DNA Mutational Analysis | 5 | 2017 | 4186 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4479 | 0.060 |
Why?
|
Neutrophils | 1 | 2017 | 3719 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 426 | 0.060 |
Why?
|
Length of Stay | 2 | 2020 | 6309 | 0.060 |
Why?
|
Watchful Waiting | 2 | 2019 | 492 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 4 | 2017 | 17446 | 0.060 |
Why?
|
Diet Surveys | 2 | 2019 | 1173 | 0.060 |
Why?
|
Observation | 1 | 2006 | 312 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2009 | 1275 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2011 | 5867 | 0.060 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2004 | 65 | 0.060 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.060 |
Why?
|
Biopsy | 3 | 2023 | 6756 | 0.060 |
Why?
|
Piperidines | 1 | 2012 | 1602 | 0.060 |
Why?
|
Levamisole | 1 | 2003 | 35 | 0.060 |
Why?
|
Nutritional Status | 1 | 2012 | 1609 | 0.060 |
Why?
|
Appetite | 1 | 2005 | 243 | 0.060 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3508 | 0.060 |
Why?
|
Anxiety | 1 | 2017 | 4297 | 0.060 |
Why?
|
Nucleocapsid | 1 | 2023 | 59 | 0.060 |
Why?
|
Estradiol | 1 | 2010 | 2020 | 0.060 |
Why?
|
Paclitaxel | 2 | 2023 | 1708 | 0.060 |
Why?
|
Chromosomes, Human, Pair 18 | 3 | 2009 | 245 | 0.060 |
Why?
|
Prodrugs | 1 | 2005 | 268 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2020 | 19905 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6544 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1146 | 0.050 |
Why?
|
Health Promotion | 1 | 2015 | 2205 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2022 | 63 | 0.050 |
Why?
|
Carotenoids | 1 | 2005 | 624 | 0.050 |
Why?
|
Nutrition Assessment | 1 | 2005 | 723 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
Genotype | 4 | 2022 | 12951 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 332 | 0.050 |
Why?
|
Genetic Testing | 1 | 2015 | 3444 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2017 | 11483 | 0.050 |
Why?
|
Poultry | 1 | 2022 | 82 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2014 | 2503 | 0.050 |
Why?
|
Furosemide | 1 | 2022 | 167 | 0.050 |
Why?
|
Niacinamide | 1 | 2024 | 417 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2013 | 288 | 0.050 |
Why?
|
Polymerase Chain Reaction | 4 | 2013 | 6171 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1640 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5686 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2518 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2019 | 10943 | 0.050 |
Why?
|
ROC Curve | 2 | 2020 | 3527 | 0.050 |
Why?
|
Intention | 1 | 2024 | 341 | 0.050 |
Why?
|
Preoperative Period | 1 | 2023 | 549 | 0.050 |
Why?
|
Republic of Korea | 2 | 2013 | 539 | 0.050 |
Why?
|
Indoles | 1 | 2009 | 1839 | 0.050 |
Why?
|
Gene Silencing | 1 | 2007 | 1538 | 0.050 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2023 | 401 | 0.050 |
Why?
|
Hematoxylin | 1 | 2020 | 64 | 0.050 |
Why?
|
Marital Status | 1 | 2022 | 437 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 72 | 0.050 |
Why?
|
Medical Record Linkage | 2 | 2012 | 284 | 0.050 |
Why?
|
Pyrimidinones | 1 | 2023 | 371 | 0.050 |
Why?
|
Tumor Burden | 2 | 2020 | 1915 | 0.050 |
Why?
|
Muscular Atrophy | 1 | 2023 | 349 | 0.050 |
Why?
|
North America | 1 | 2004 | 1249 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2017 | 599 | 0.050 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 275 | 0.050 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1405 | 0.050 |
Why?
|
Liver | 2 | 2019 | 7474 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 1 | 2006 | 1203 | 0.050 |
Why?
|
Poverty Areas | 1 | 2021 | 275 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 624 | 0.050 |
Why?
|
Drug Carriers | 1 | 2004 | 693 | 0.040 |
Why?
|
Health Surveys | 3 | 2017 | 4037 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 648 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 25043 | 0.040 |
Why?
|
Cancer Care Facilities | 2 | 2014 | 402 | 0.040 |
Why?
|
Public Health | 1 | 2013 | 2603 | 0.040 |
Why?
|
Patient Dropouts | 2 | 2013 | 421 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2009 | 2421 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2023 | 976 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2017 | 2948 | 0.040 |
Why?
|
Sulfonamides | 1 | 2009 | 1938 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 1999 | 13815 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2020 | 5078 | 0.040 |
Why?
|
Macrophage Activation | 2 | 2020 | 558 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2019 | 12026 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 690 | 0.040 |
Why?
|
Canada | 2 | 2017 | 2065 | 0.040 |
Why?
|
Obesity, Abdominal | 1 | 2022 | 361 | 0.040 |
Why?
|
Edema | 1 | 2023 | 789 | 0.040 |
Why?
|
Pyrazoles | 1 | 2009 | 1972 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 553 | 0.040 |
Why?
|
Rectus Abdominis | 1 | 2019 | 97 | 0.040 |
Why?
|
Trans Fatty Acids | 1 | 2019 | 153 | 0.040 |
Why?
|
Base Sequence | 4 | 2012 | 12797 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2011 | 5172 | 0.040 |
Why?
|
Molecular Sequence Data | 3 | 1999 | 18111 | 0.040 |
Why?
|
Dietary Fats, Unsaturated | 1 | 2019 | 226 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7322 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 712 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 801 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3870 | 0.040 |
Why?
|
Depression | 1 | 2017 | 7766 | 0.040 |
Why?
|
MAP Kinase Signaling System | 2 | 2018 | 1526 | 0.040 |
Why?
|
Epirubicin | 1 | 2017 | 80 | 0.040 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 703 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 602 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 809 | 0.040 |
Why?
|
Fatigue | 1 | 2005 | 1531 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2010 | 2071 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1641 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2003 | 738 | 0.040 |
Why?
|
Fatty Acids | 1 | 2005 | 1809 | 0.040 |
Why?
|
North Carolina | 1 | 2018 | 315 | 0.040 |
Why?
|
Automation | 1 | 2020 | 584 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2023 | 1725 | 0.040 |
Why?
|
Doxorubicin | 1 | 2024 | 2234 | 0.040 |
Why?
|
Cell Line, Transformed | 1 | 1999 | 898 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 1 | 2023 | 1157 | 0.040 |
Why?
|
Transcription, Genetic | 2 | 1992 | 7722 | 0.040 |
Why?
|
Pain | 2 | 2022 | 4986 | 0.040 |
Why?
|
COS Cells | 1 | 1999 | 1161 | 0.040 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2022 | 1240 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4328 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 924 | 0.040 |
Why?
|
Hepacivirus | 1 | 2024 | 1379 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 2879 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3508 | 0.030 |
Why?
|
Cadherins | 1 | 2001 | 907 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2017 | 188 | 0.030 |
Why?
|
DNA Glycosylases | 1 | 2017 | 128 | 0.030 |
Why?
|
Postprandial Period | 1 | 2017 | 292 | 0.030 |
Why?
|
Waist Circumference | 1 | 2020 | 917 | 0.030 |
Why?
|
Motivation | 2 | 2019 | 1971 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2020 | 1100 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 161 | 0.030 |
Why?
|
Pancreas | 1 | 2022 | 1686 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2021 | 1142 | 0.030 |
Why?
|
Microsatellite Repeats | 2 | 2009 | 802 | 0.030 |
Why?
|
Patient Preference | 1 | 2022 | 890 | 0.030 |
Why?
|
Nuclear Proteins | 4 | 2017 | 5853 | 0.030 |
Why?
|
Europe | 1 | 2002 | 3339 | 0.030 |
Why?
|
Blotting, Northern | 1 | 1997 | 1581 | 0.030 |
Why?
|
Penetrance | 1 | 2017 | 381 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2001 | 1364 | 0.030 |
Why?
|
Nutritive Value | 1 | 2018 | 339 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1769 | 0.030 |
Why?
|
Chickens | 1 | 1997 | 865 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2020 | 725 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 629 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2001 | 1602 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2309 | 0.030 |
Why?
|
Epidemiologic Methods | 2 | 2010 | 1364 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1969 | 0.030 |
Why?
|
DNA | 2 | 2024 | 7301 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2029 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1999 | 2839 | 0.030 |
Why?
|
Food, Fortified | 1 | 2015 | 191 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5751 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2022 | 1826 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1316 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2001 | 3144 | 0.030 |
Why?
|
Demography | 1 | 2019 | 1656 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 553 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1782 | 0.030 |
Why?
|
Life Expectancy | 1 | 2020 | 1184 | 0.030 |
Why?
|
Leisure Activities | 1 | 2015 | 311 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 705 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2021 | 2699 | 0.030 |
Why?
|
Fruit | 1 | 2019 | 1142 | 0.030 |
Why?
|
Leukocytes | 1 | 2022 | 2043 | 0.030 |
Why?
|
Gene Expression | 2 | 2014 | 7799 | 0.030 |
Why?
|
Vegetables | 1 | 2019 | 1182 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 618 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1997 | 2050 | 0.030 |
Why?
|
Palliative Care | 2 | 2014 | 3493 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 764 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2013 | 105 | 0.030 |
Why?
|
Glioblastoma | 1 | 2008 | 3481 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3798 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2016 | 673 | 0.030 |
Why?
|
Macrophages | 2 | 2021 | 5655 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 781 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2046 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2133 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2005 | 3396 | 0.030 |
Why?
|
Pancreatectomy | 1 | 2017 | 804 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2008 | 2916 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2019 | 2539 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2023 | 13033 | 0.030 |
Why?
|
Organ Size | 1 | 2017 | 2252 | 0.030 |
Why?
|
Signal Transduction | 5 | 2014 | 23403 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2016 | 5524 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2009 | 1261 | 0.030 |
Why?
|
Colonoscopy | 1 | 2020 | 1367 | 0.030 |
Why?
|
Program Evaluation | 1 | 2020 | 2488 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2016 | 1880 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 6489 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2886 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 18 | 0.020 |
Why?
|
Minnesota | 1 | 2011 | 344 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4420 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6459 | 0.020 |
Why?
|
Neoplasm Transplantation | 2 | 2011 | 2085 | 0.020 |
Why?
|
Trans-Activators | 1 | 2001 | 2924 | 0.020 |
Why?
|
Eating | 1 | 2018 | 1536 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 390 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 13881 | 0.020 |
Why?
|
RNA Probes | 1 | 1990 | 113 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 605 | 0.020 |
Why?
|
Internet | 1 | 2023 | 3064 | 0.020 |
Why?
|
Patient Participation | 1 | 2020 | 1457 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 664 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5391 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2022 | 2624 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1956 | 0.020 |
Why?
|
Genomic Library | 1 | 1990 | 193 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1999 | 4740 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2012 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2012 | 411 | 0.020 |
Why?
|
Puerto Rico | 1 | 2011 | 356 | 0.020 |
Why?
|
Escherichia coli | 1 | 2022 | 4217 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4245 | 0.020 |
Why?
|
Skin | 1 | 2023 | 4364 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 2959 | 0.020 |
Why?
|
Viral Proteins | 1 | 2017 | 1900 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1275 | 0.020 |
Why?
|
Caenorhabditis elegans | 1 | 1999 | 1419 | 0.020 |
Why?
|
Restriction Mapping | 1 | 1990 | 878 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 552 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1708 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 9648 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 1992 | 382 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 783 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 367 | 0.020 |
Why?
|
DNA Probes | 1 | 1990 | 560 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 780 | 0.020 |
Why?
|
Phosphorylation | 2 | 2010 | 8436 | 0.020 |
Why?
|
Spermatogenesis | 1 | 1990 | 262 | 0.020 |
Why?
|
Blotting, Western | 1 | 1997 | 5179 | 0.020 |
Why?
|
Stroke | 1 | 2012 | 9981 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 1085 | 0.020 |
Why?
|
Gene Deletion | 1 | 1997 | 2751 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 135 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 783 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1086 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2003 | 3507 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1992 | 1263 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2593 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6365 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 123 | 0.020 |
Why?
|
Calcium Channels, T-Type | 1 | 2008 | 34 | 0.020 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 56 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2716 | 0.020 |
Why?
|
Seasons | 1 | 2013 | 1493 | 0.020 |
Why?
|
Physician's Role | 1 | 2015 | 943 | 0.020 |
Why?
|
Mice | 5 | 2014 | 81183 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7785 | 0.020 |
Why?
|
Epigenesis, Genetic | 2 | 2012 | 3647 | 0.020 |
Why?
|
Introns | 1 | 1990 | 991 | 0.020 |
Why?
|
Immunotherapy | 1 | 2003 | 4445 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 25625 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2018 | 1622 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 232 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 175 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 464 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 2892 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3610 | 0.020 |
Why?
|
Wnt Proteins | 1 | 2011 | 721 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 1213 | 0.020 |
Why?
|
Patient Care Team | 1 | 2018 | 2531 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1344 | 0.020 |
Why?
|
History, 21st Century | 1 | 2013 | 1534 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1655 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 681 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2063 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3114 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 48 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1486 | 0.020 |
Why?
|
Nerve Tissue Proteins | 2 | 2010 | 4462 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4215 | 0.020 |
Why?
|
Child | 3 | 2021 | 77709 | 0.020 |
Why?
|
Species Specificity | 1 | 1990 | 2478 | 0.020 |
Why?
|
Alleles | 1 | 1997 | 6933 | 0.020 |
Why?
|
Infant | 2 | 2021 | 35136 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2009 | 1588 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1504 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 666 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 385 | 0.020 |
Why?
|
Organ Specificity | 1 | 1990 | 2008 | 0.020 |
Why?
|
RNA Stability | 1 | 2007 | 321 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3772 | 0.020 |
Why?
|
Child, Preschool | 2 | 2021 | 41006 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 666 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3689 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 3002 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6622 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2020 | 19229 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5137 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2008 | 1850 | 0.010 |
Why?
|
Mortality | 1 | 2015 | 2864 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13989 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
Remission Induction | 1 | 2008 | 2386 | 0.010 |
Why?
|
Telemedicine | 1 | 2020 | 2872 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3505 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3920 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 1114 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4751 | 0.010 |
Why?
|
Desmogleins | 1 | 2001 | 3 | 0.010 |
Why?
|
alpha Catenin | 1 | 2001 | 38 | 0.010 |
Why?
|
Radiography | 1 | 2012 | 7023 | 0.010 |
Why?
|
Desmoplakins | 1 | 2001 | 62 | 0.010 |
Why?
|
Chronic Disease | 1 | 2016 | 9146 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 1959 | 0.010 |
Why?
|
Genetic Markers | 1 | 2007 | 2634 | 0.010 |
Why?
|
Boston | 1 | 2013 | 9313 | 0.010 |
Why?
|
Cell Aggregation | 1 | 2001 | 244 | 0.010 |
Why?
|
Heterozygote | 1 | 2007 | 2804 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4803 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2109 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 2001 | 6314 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2010 | 3086 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15540 | 0.010 |
Why?
|
Primary Health Care | 1 | 2015 | 4558 | 0.010 |
Why?
|
Postmenopause | 1 | 2006 | 2461 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2014 | 4468 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2001 | 1526 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3567 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9727 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 16689 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 12072 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10262 | 0.010 |
Why?
|
Massachusetts | 1 | 2007 | 8663 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3462 | 0.010 |
Why?
|
Rats | 1 | 1990 | 24260 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9583 | 0.010 |
Why?
|
Transfection | 1 | 2001 | 5892 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2006 | 5021 | 0.010 |
Why?
|
Receptors, Interleukin-1 | 1 | 1992 | 262 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2001 | 2866 | 0.010 |
Why?
|
Clinical Competence | 1 | 2007 | 4687 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15295 | 0.010 |
Why?
|
Feedback | 1 | 1992 | 795 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 1992 | 2126 | 0.000 |
Why?
|
Cell Division | 1 | 1992 | 4568 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1992 | 6386 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 35421 | 0.000 |
Why?
|